Trial Profile
A Phase 1 Randomized,Double-Blind,Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1603 in Chinese Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2019
Price :
$35
*
At a glance
- Drugs ZSP-1603 (Primary)
- Indications Idiopathic pulmonary fibrosis; Solid tumours
- Focus Adverse reactions
- Sponsors Guangdong Zhongsheng Pharmaceutical
- 22 Oct 2019 Status changed from recruiting to completed.
- 16 Aug 2018 New trial record